GlaxoSmithKline (LON:GSK) Now Covered by JPMorgan Chase & Co.

Share on StockTwits

JPMorgan Chase & Co. initiated coverage on shares of GlaxoSmithKline (LON:GSK) in a report issued on Tuesday, MarketBeat.com reports. The brokerage set a “neutral” rating and a GBX 1,700 ($22.21) price target on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 2.43% from the company’s current price.

A number of other analysts also recently issued reports on the company. Goldman Sachs Group set a GBX 1,900 ($24.83) target price on GlaxoSmithKline and gave the stock a “buy” rating in a research note on Monday, July 22nd. HSBC set a GBX 1,942 ($25.38) target price on GlaxoSmithKline and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Jefferies Financial Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research note on Friday, May 24th. Liberum Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research report on Tuesday, July 2nd. Finally, Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research report on Wednesday, July 10th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 1,638.06 ($21.40).

Shares of GSK opened at GBX 1,659.60 ($21.69) on Tuesday. GlaxoSmithKline has a 52-week low of GBX 1,408.80 ($18.41) and a 52-week high of GBX 1,749.40 ($22.86). The firm has a market cap of $82.78 billion and a P/E ratio of 18.69. The business has a fifty day moving average of GBX 1,651.25. The company has a quick ratio of 0.44, a current ratio of 0.71 and a debt-to-equity ratio of 1,127.74.

In other GlaxoSmithKline news, insider Vivienne Cox acquired 434 shares of the business’s stock in a transaction that occurred on Wednesday, July 24th. The stock was purchased at an average cost of GBX 1,654 ($21.61) per share, with a total value of £7,178.36 ($9,379.80). Insiders have purchased a total of 456 shares of company stock valued at $753,737 over the last three months.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Further Reading: What is a conference call?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

EJF Capital LLC Lowers Stake in Sandy Spring Bancorp Inc.
EJF Capital LLC Lowers Stake in Sandy Spring Bancorp Inc.
EJF Capital LLC Buys New Position in Radian Group Inc
EJF Capital LLC Buys New Position in Radian Group Inc
EJF Capital LLC Has $7.26 Million Position in Rhinebeck Bancorp Inc
EJF Capital LLC Has $7.26 Million Position in Rhinebeck Bancorp Inc
EJF Capital LLC Buys Shares of 402,288 Mainstreet Bank Common Stock
EJF Capital LLC Buys Shares of 402,288 Mainstreet Bank Common Stock
EJF Capital LLC Grows Stock Position in First Savings Financial Group Inc
EJF Capital LLC Grows Stock Position in First Savings Financial Group Inc
SB Financial Group Inc  Shares Bought by EJF Capital LLC
SB Financial Group Inc Shares Bought by EJF Capital LLC


© 2006-2019 Ticker Report